Entering text into the input field will update the search result below

Ocuphire completes enrollment in pediatric patients study of Nyxol eye drops

Mar. 08, 2022 10:49 AM ETOcuphire Pharma, Inc. (OCUP)By: SA News Team

Macro shot of female eye, iris, cropped on black background, usable as creative background

Epiximages/iStock via Getty Images

  • Ocuphire Pharma (NASDAQ:OCUP) said it completed enrollment in a study, dubbed MIRA-4, evaluating its eye drops Nyxol to reverse pharmacologically-induced mydriasis (RM) in 23 children aged 3-to-11 years old.
  • RM is an unusual dilation or widening

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About OCUP

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
Ocuphire Pharma, Inc.
NGM Biopharmaceuticals, Inc.
Clearside Biomedical, Inc.
Eyenovia, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.